Literature DB >> 23677471

Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells.

Thomas Lindenstrøm1, Niels Peter Hell Knudsen, Else Marie Agger, Peter Andersen.   

Abstract

The bacille Calmette-Guérin vaccine provides very efficient protection in standard animal models of Mycobacterium tuberculosis challenge. We show in this article that although bacille Calmette-Guérin controlled M. tuberculosis growth for 7 wk of infection, the protection was gradually lost as the infection entered the chronic phase. The regrowth of M. tuberculosis coincided with an almost complete disappearance of IL-2-producing CD4 T cells. Booster vaccination with a subunit vaccine (Ag85B-ESAT-6+CAF01) expanded IL-2(+) CD4(+) T cell coexpressing either TNF-α or TNF-α/IFN-γ, and the maintenance of this population in the late stage of infection was associated with enhanced control of bacterial growth. The IL-2(+) CD4(+) T cell subsets were KLRG1(-) (nonterminally differentiated), were found to be CD62L(high), and further maintained a pronounced proliferative and cytokine-producing potential in the draining lymph nodes, when the animals were challenged 2 y postvaccination. These results suggest that the CD4(+) KLRG1(-) IL-2-secreting subsets are central memory T cells with the potential to continuously replenish the T cells at the site of infection and prevent attrition and functional exhaustion.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23677471     DOI: 10.4049/jimmunol.1300248

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  85 in total

1.  Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis.

Authors:  Albanus O Moguche; Munyaradzi Musvosvi; Adam Penn-Nicholson; Courtney R Plumlee; Helen Mearns; Hennie Geldenhuys; Erica Smit; Deborah Abrahams; Virginie Rozot; One Dintwe; Søren T Hoff; Ingrid Kromann; Morten Ruhwald; Peter Bang; Ryan P Larson; Shahin Shafiani; Shuyi Ma; David R Sherman; Alessandro Sette; Cecilia S Lindestam Arlehamn; Denise M McKinney; Holden Maecker; Willem A Hanekom; Mark Hatherill; Peter Andersen; Thomas J Scriba; Kevin B Urdahl
Journal:  Cell Host Microbe       Date:  2017-06-14       Impact factor: 21.023

2.  A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.

Authors:  M Tameris; D A Hokey; V Nduba; J Sacarlal; F Laher; G Kiringa; K Gondo; E M Lazarus; G E Gray; S Nachman; H Mahomed; K Downing; B Abel; T J Scriba; J B McClain; M G Pau; J Hendriks; V Dheenadhayalan; S Ishmukhamedov; A K K Luabeya; H Geldenhuys; B Shepherd; G Blatner; V Cardenas; R Walker; W A Hanekom; J Sadoff; M Douoguih; L Barker; M Hatherill
Journal:  Vaccine       Date:  2015-04-28       Impact factor: 3.641

3.  Use of antigen-specific interleukin-2 to differentiate between cattle vaccinated with Mycobacterium bovis BCG and cattle infected with M. bovis.

Authors:  Shelley G Rhodes; Lucy C McKinna; Sabine Steinbach; Gilly S Dean; Bernardo Villarreal-Ramos; Adam O Whelan; C Pirson; Gareth J Jones; Derek Clifford; H Martin Vordermeier
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

Review 4.  Tuberculosis vaccine types and timings.

Authors:  Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

5.  Protein energy malnutrition during vaccination has limited influence on vaccine efficacy but abolishes immunity if administered during Mycobacterium tuberculosis infection.

Authors:  Truc Hoang; Else Marie Agger; Joseph P Cassidy; Jan P Christensen; Peter Andersen
Journal:  Infect Immun       Date:  2015-03-09       Impact factor: 3.441

6.  Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of Tuberculosis.

Authors:  Mark T Orr; Hillarie Plessner Windish; Elyse A Beebe; David Argilla; Po-Wei D Huang; Valerie A Reese; Steven G Reed; Rhea N Coler
Journal:  J Infect Dis       Date:  2015-01-30       Impact factor: 5.226

Review 7.  Metabolic reprogramming and apoptosis sensitivity: Defining the contours of a T cell response.

Authors:  Kelsey Voss; Sasha E Larsen; Andrew L Snow
Journal:  Cancer Lett       Date:  2017-09-01       Impact factor: 8.679

8.  Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.

Authors:  Ming Zhang; Chunsheng Dong; Sidong Xiong
Journal:  Hum Vaccin Immunother       Date:  2016-12-14       Impact factor: 3.452

9.  Robust Reconstitution of Tuberculosis-Specific Polyfunctional CD4+ T-Cell Responses and Rising Systemic Interleukin 6 in Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome.

Authors:  Shruthi Ravimohan; Neo Tamuhla; Kebatshabile Nfanyana; Andrew P Steenhoff; Rona Letlhogile; Ian Frank; Rob Roy MacGregor; Robert Gross; Drew Weissman; Gregory P Bisson
Journal:  Clin Infect Dis       Date:  2015-11-26       Impact factor: 9.079

10.  Enhanced protective efficacy against Mycobacterium tuberculosis afforded by BCG prime-DNA boost regimen in an early challenge mouse model is associated with increased splenic interleukin-2-producing CD4 T-cell frequency post-vaccination.

Authors:  Han Kang; Qin Yuan; Hui Ma; Zhi-Dong Hu; De-Ping Han; Kang Wu; Douglas B Lowrie; Xiao-Yong Fan
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.